Gilead’s new drug keeps 56% of lymphoma trial patients alive  Pharmacy Today, American Pharmacists Association, pharmacist.comGilead Sciences’ (GILD) Kite LT Pivotal ZUMA-1 Study of Yescarta Shows 42% of Patients Remained in Response …  StreetInsider.comFull coverage http://www.pharmacist.com/article/gileads-new-drug-keeps-56-lymphoma-trial-patients-alive

Advertisements